Lineage Cell Therapeutics’ (LCTX) “Buy” Rating Reiterated at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) in a research note published on Friday morning,Benzinga reports. The brokerage currently has a $2.00 price objective on the stock.

Separately, HC Wainwright upped their price target on Lineage Cell Therapeutics from $7.00 to $9.00 and gave the stock a “buy” rating in a report on Wednesday, December 4th.

Lineage Cell Therapeutics Stock Up 14.6 %

NYSEAMERICAN LCTX opened at $0.59 on Friday. The stock has a market cap of $130.07 million, a price-to-earnings ratio of -4.92 and a beta of 1.16. Lineage Cell Therapeutics has a fifty-two week low of $0.48 and a fifty-two week high of $1.61.

Institutional Investors Weigh In On Lineage Cell Therapeutics

Large investors have recently bought and sold shares of the stock. Raffles Associates LP increased its position in shares of Lineage Cell Therapeutics by 35.8% in the 2nd quarter. Raffles Associates LP now owns 4,357,781 shares of the company’s stock valued at $4,346,000 after purchasing an additional 1,147,800 shares during the last quarter. Barclays PLC grew its stake in shares of Lineage Cell Therapeutics by 311.3% during the third quarter. Barclays PLC now owns 211,300 shares of the company’s stock worth $192,000 after purchasing an additional 159,924 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in Lineage Cell Therapeutics by 35.7% in the second quarter. Bank of New York Mellon Corp now owns 435,958 shares of the company’s stock valued at $435,000 after buying an additional 114,762 shares during the last quarter. GSA Capital Partners LLP purchased a new position in Lineage Cell Therapeutics in the third quarter valued at $84,000. Finally, Geode Capital Management LLC raised its stake in Lineage Cell Therapeutics by 2.3% in the third quarter. Geode Capital Management LLC now owns 3,679,280 shares of the company’s stock valued at $3,331,000 after buying an additional 83,274 shares in the last quarter. Hedge funds and other institutional investors own 62.47% of the company’s stock.

Lineage Cell Therapeutics Company Profile

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.